Investment
Features
FeesSafety
Academy
More
Pluang+

Socialism gains political ground in US, prompting free market advocates to strengthen their case for capitalism.

Market News
19 Oct 2026
Fox Business
View Source
Neutral
Socialism gains political ground in US, prompting free market advocates to strengthen their case for capitalism.

Socialism is rising in popularity within U.S. politics, particularly among those identifying as democratic socialists who seek a system more like European social democracy. Sam Gregg of the American Institute for Economic Research highlights the need for free market supporters to improve their messaging by combining economic arguments with moral appeals about liberty and opportunity. Polls show socialism's favorability increasing but still trailing capitalism, which remains favored by a majority. Advocates argue capitalism not only drives economic prosperity but also protects broader freedoms essential to the American Dream.

Regarding the discussion on capitalism and socialism, here is Pluang's market snapshot as of Oct 20, 2026 07:01 WIB: Among 150 priced US stocks tradable on Pluang, 60 rose and 90 fell today. Notable movers include DraftKings Inc (DKNG) at USD 19.72 with a 4.34% increase and a typical hold time of 56 days, Marvell Technology Inc (MRVL) at USD 237.65 with a 4.31% increase and a typical hold time of 43 days, and Moderna, Inc. (MRNA) at USD 227.22 with a 4.22% increase and a typical hold time of 59 days. The most notable figure is the 90% sell order activity on DKNG.

More News

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
2 hours ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
2 hours ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
3 hours ago
Shiba Inu euro trading shows wide spread gaps, impacting trader costs across exchanges.

Shiba Inu euro trading shows wide spread gaps, impacting trader costs across exchanges.

On October 19, Shiba Inu (SHIB) trading against the euro revealed significant differences in bid-ask spreads across exchanges, with Kraken and Bit2Me showing tight spreads around 0.022%, while WhiteBIT had a much wider spread of 0.670%. This large va...

Market News
Neutral
4 hours ago
Researchers simulate a 50-qubit quantum computer using NVIDIA's JUPITER, setting a new benchmark in quantum computing.

Researchers simulate a 50-qubit quantum computer using NVIDIA's JUPITER, setting a new benchmark in quantum computing.

The Jülich Supercomputing Centre and NVIDIA used the JUPITER supercomputer to simulate a universal 50-qubit quantum computer, surpassing their previous 48-qubit record from 2019. This full-state simulation required 2,048 TiB of memory, achieved throu...

Protocol Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App